UPMC has been selected as a center for the VICTORIA Study, a randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal Phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator vericiguat in subjects with heart failure with reduced ejection fraction (HFrEF).

We are currently enrolling men and women who have been diagnosed with heart failure with a reduced ejection fraction. The primary purpose of this study is to evaluate the effectiveness of the study drug, vericiguat, compared to placebo plus background standard-of-care therapy, in increasing the time to first occurrence of the composite of cardiovascular death or heart failure hospitalization in subjects with HFrEF.

Vericiguat acts on the nitric oxide pathway; the Phase II trial (SOCRATES-REDUCED) was published in JAMA 2015, which suggested a dose-related reduction in NT-proBNP on top of standard of care heart failure treatment.

Which patients are eligible?

Potential candidates for VICTORIA must meet the following primary inclusion criteria:

  • Diagnosis of chronic heart failure with an EF of <45 percent
  • NYHA Class II-IV
  • 18 years of age or older
  • A previous HF hospitalization within six months prior to randomization, or have had IV diuretic treatment for HF (without hospitalization) within three months prior to randomization

Contact us

For a full list of inclusion/exclusion criteria or to refer a patient:
Marc Simon, MD, is the principal investigator at UPMC. If you know a patient you believe may qualify, please call Kristin Shoemaker, RN, BSN, CCRC, research nurse coordinator at 412-692-2769 or email